RELIANCE IND Q2

Q2 CAPEX DOWN 1 % TO 38,153 CR QOQ

NET DEBT FALLS 5 % TO 1.17 LKH CR QOQ

RELIANCE INDUSTRIES Q2 FY27 – RECORD QUARTERLY PERFORMANCE

• Revenue hits record ₹3,62,268 Cr, up 27.8% YoY.

• Record quarterly EBITDA at ₹62,409 Cr, up 23.9% YoY.

• Quarterly PAT reaches new high of ₹29,550 Cr, up 33.8% YoY.

• 1H FY27 PAT crosses ₹50,000 Cr.

• O2C delivers its best-ever performance, with EBITDA at ₹25,203 Cr, up 67.9% YoY.

• Digital Services EBITDA at ₹22,223 Cr, up 17.7% YoY.

• Jio Platforms makes a landmark capital market debut as India's second-most valuable company.

LIC HOUSING FINANCE Q2 FY27 RESULTS

• Net Profit: ₹1,507 Cr ↑12% (YoY) | ↑1% (QoQ)

• Net Interest Income (NII): ₹2,099 Cr ↑3% (YoY) | ↑1% (QoQ)

TEMPSENS INSTRUMENTS Q2 FY27 (CONSOLIDATED)

• Net Profit: ₹19.44 Cr ↑20.23% (YoY) | ↑19.49% (QoQ)

• Revenue: ₹136.32 Cr ↑34.02% (YoY) | ↑14.83% (QoQ)

• EBITDA: ₹25.01 Cr ↑12.47% (YoY) | ↑5.27% (QoQ)

• EBITDA Margin: 18.35% vs 21.86% (YoY) | 20.01% (QoQ)

UPDATER SERVICES Q2 FY27 RESULTS

• Net Profit: ₹32 Cr ↑62% (YoY) | ↑6% (QoQ)

• Revenue: ₹812 Cr ↑11% (YoY) | ↑6% (QoQ)

• EBITDA: ₹43 Cr ↑37% (YoY) | ↑2% (QoQ)

• EBITDA Margin: 5.3% vs 4.3% (YoY) | 5.5% (QoQ)

INDRAPRASTHA GAS (IGL) Q2 FY27 (CONSOLIDATED)

• Net Profit: ₹24 Cr ↓94% (YoY) | ↓90% (QoQ)

• Revenue: ₹5,615 Cr ↑26% (YoY) | ↑11% (QoQ)

• Other Income: ₹136 Cr vs ₹95 Cr (YoY) | ₹102 Cr (QoQ)

• EPS: ₹0.20 ↓94% (YoY) | ↓91% (QoQ)

• PAT declined sharply compared with previous quarters.

Trump on Iran:

They had a lovely navy, 159 ships.

I was a little angry at my people. I said, "Why didn't you save the damn ships? They were pretty good."

Trump on Iran:

I want you to remember something very important.

America did not start the war with Iran.

Trump:

They say "We're going to impeach Trump for trying to stop Iran from having a nuclear weapon."

I said, "No, no, take the word trying out. For stopping Iran. We stopped them."

SUN PHARMA – Q2 FY27 CONCALL HIGHLIGHTS

📊 FINANCIAL PERFORMANCE

• Revenue: ₹16,100 Cr (+11.8% YoY).

• Gross Margin: 80.8%, supported by better product mix and favourable currency.

• EBITDA: ₹4,744 Cr (+4.8% YoY).

• EBITDA Margin: 29.3%.

• Adjusted Net Profit: ₹3,162 Cr.

• H1 FY27 Revenue: ₹31,284 Cr (+11% YoY).

• H1 EBITDA Margin: 29.1%.

• Net Cash Position: $3.3 billion.

SUN PHARMA – Q2 FY27 CONCALL HIGHLIGHTS

🌏 SEGMENT-WISE PERFORMANCE

🇮🇳 India Formulations
• Revenue: ₹5,552 Cr (+17.3% YoY).
• Contributed 34.5% of total sales.

🇺🇸 US Business
• Revenue: $455 million (-8.2% YoY).
• Sequential growth of 6.5%.
• Decline mainly due to lenalidomide erosion.

🌍 Global Innovative Medicines
• Revenue: $356 million (+6.9% YoY).
• Contributed 21.1% of total sales.

🌐 Emerging Markets
• Revenue: $350 million (+7.6% YoY).
• Growth driven by branded generics and innovative medicines.

🌏 Rest of the World
• Formulation revenue: $241 million.

SUN PHARMA – Q2 FY27 CONCALL HIGHLIGHTS

🌏 SEGMENT-WISE PERFORMANCE

🇮🇳 India Formulations
• Revenue: ₹5,552 Cr (+17.3% YoY).
• Contributed 34.5% of total sales.

🇺🇸 US Business
• Revenue: $455 million (-8.2% YoY).
• Sequential growth of 6.5%.
• Decline mainly due to lenalidomide erosion.

🌍 Global Innovative Medicines
• Revenue: $356 million (+6.9% YoY).
• Contributed 21.1% of total sales.

🌐 Emerging Markets
• Revenue: $350 million (+7.6% YoY).
• Growth driven by branded generics and innovative medicines.

🌏 Rest of the World
• Formulation revenue: $241 million.

SUN PHARMA – Q2 FY27 CONCALL HIGHLIGHTS

💊 KEY PRODUCT & PIPELINE UPDATES

• Illumia faced a slowdown in the US due to market and execution factors. Received US approval for psoriatic arthritis; soft launch planned for November.

• ONLOXIT received preferred recommendation in NCCN guidelines. New long-term data showed efficacy and tolerability.

• Launched 5 new generic products in the US during Q2.

• Partnership with Leap Therapeutics for Liraglutide to expand the innovative portfolio for cholesterol management outside the US and China.

• Generic Semaglutide launched by a partner in Brazil. Already commercialised in India and South Africa.

• Launched 15 new products in India during Q2.

🔬 R&D AND INNOVATION

• Q2 R&D Spend: ₹778 Cr, representing 4.8% of sales.

• Innovative R&D accounted for 32.4% of total R&D expenditure.

• Management expects R&D spending to increase significantly in H2 FY27.

SUN PHARMA – Q2 FY27 CONCALL HIGHLIGHTS

🎯 OUTLOOK & CORPORATE DEVELOPMENTS

• FY27 Revenue Growth Guidance: High-single-digit growth maintained.

• FY27 R&D Spend Guidance: 6–7% of sales.

• Organon acquisition expected to close by Q4 FY27; most regulatory approvals secured.

• Voluntary recall of 11 ophthalmic products.

• Temporarily halted manufacturing at Assam plant for remedial actions.

MEGA FLEX PLASTICS H1 FY27

• Net Profit: ₹3.31 Cr ↑100.22% (YoY) | ↓41.01% QoQ (QoQ)

• Revenue: ₹46.41 Cr ↑57.98% (YoY) | ↓4.69% YoY (QoQ)

• EBITDA: ₹3.46 Cr ↑252.75% (YoY) | ↓51.20% (QoQ)

• EBITDA Margin: 7.45% vs 3.34% (YoY) | 14.56% (QoQ)

RULKA ELECTRICALS H1 FY27

• Net Profit: ₹3.03 Cr ↑99.66% (YoY) | ↑70.91% (QoQ)

• Revenue: ₹75.21 Cr ↑36.36% (YoY) | ↑36.61% (QoQ)

• EBITDA: ₹5.00 Cr ↑83.04% (YoY) | ↑76.34% (QoQ)

• EBITDA Margin: 6.65% vs 4.96% (YoY) | 5.15% (QoQ)

RULKA ELECTRICALS H1 FY27

• Net Profit: ₹3.03 Cr ↑99.66% (YoY) | ↑70.91% QoQ

• Revenue: ₹75.21 Cr ↑36.36% (YoY) | ↑36.61% (QoQ)

• EBITDA: ₹5.00 Cr ↑83.04% (YoY) | ↑76.34% (QoQ)

• EBITDA Margin: 6.65% vs 4.96% (YoY) | 5.15% (QoQ)

URBAN ENVIRO WASTE MANAGEMENT H1 FY27

• Net Profit: ₹8.47 Cr ↓6.77% (YoY) | ↑46.30% (QoQ)

• Revenue: ₹94.17 Cr ↑8.67% (YoY) | ↓1.37% (QoQ)

• EBITDA: ₹17.83 Cr ↑12.63% (YoY) | ↑12.45% (QoQ)

• EBITDA Margin: 18.94% vs 18.27% (YoY) | 16.61% (QoQ)

UPSURGE SEEDS OF AGRICULTURE H1 FY27 (STANDALONE)

• Net Profit: ₹3.32 Cr ↑30.95% (YoY) | ↓32.70% QoQ

• Revenue: ₹60.57 Cr ↑29.32% (YoY) | ↓4.76% (QoQ)

• EBITDA: ₹6.33 Cr ↑6.87% (YoY) | ↓22.72% (QoQ)

• EBITDA Margin: 10.46% vs 12.66% (YoY) | 12.89% (QoQ)

ARUNAYA ORGANICS H1 FY27

• Net Profit: ₹1.98 Cr ↑2.80% (YoY) | ↑10.37% (QoQ)

• Revenue: ₹50.24 Cr ↓7.57% (YoY) | ↑2.74% (QoQ)

• EBITDA: ₹3.07 Cr ↓0.49% (YoY) | ↓5.58% (QoQ)

• EBITDA Margin: 6.11% vs 5.68% (YoY) | 6.65% (QoQ)

ELEGANZ INTERIORS H1 FY27 (CONSOLIDATED)

• Net Profit: ₹7.06 Cr ↑206.68% (YoY) | ↓64.37% (QoQ)

• Revenue: ₹200.06 Cr ↑80.23% (YoY) | ↓30.83% (QoQ)

• EBITDA: ₹14.10 Cr ↑197.49% (YoY) | ↓52.38% (QoQ)

• EBITDA Margin: 7.05% vs 4.27% (YoY) | 10.24% (QoQ)